Mizuho Downgrades Amedisys Inc (NASDAQ:AMED) to Neutral
Mizuho cut shares of Amedisys Inc (NASDAQ:AMED) from a buy rating to a neutral rating in a research note issued to investors on Wednesday morning, MarketBeat reports. Mizuho currently has $50.00 price objective on the health services provider’s stock.
AMED has been the topic of several other reports. Royal Bank Of Canada reissued a hold rating and issued a $56.00 target price on shares of Amedisys in a research report on Monday, June 5th. BidaskClub downgraded Amedisys from a strong-buy rating to a buy rating in a research report on Wednesday, July 12th. Stephens upped their target price on Amedisys from $50.00 to $54.00 and gave the company an equal weight rating in a research report on Thursday, May 4th. Benchmark Co. reissued a hold rating and issued a $57.00 target price (up from $50.00) on shares of Amedisys in a research report on Wednesday, May 3rd. Finally, Zacks Investment Research downgraded Amedisys from a buy rating to a hold rating in a research report on Tuesday, May 2nd. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $56.50.
Amedisys (NASDAQ:AMED) opened at 46.66 on Wednesday. The stock has a 50 day moving average price of $60.41 and a 200-day moving average price of $54.02. The stock has a market capitalization of $1.58 billion, a P/E ratio of 39.88 and a beta of 0.94. Amedisys has a 1-year low of $34.58 and a 1-year high of $65.91.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The firm had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. During the same quarter in the prior year, the business posted $0.42 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Equities research analysts expect that Amedisys will post $2.14 EPS for the current year.
In related news, Director Bruce D. Perkins purchased 500 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were bought at an average cost of $59.69 per share, with a total value of $29,845.00. Following the transaction, the director now owns 13,331 shares of the company’s stock, valued at $795,727.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jake L. Netterville sold 10,000 shares of the stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the sale, the director now directly owns 77,499 shares in the company, valued at $4,649,940. The disclosure for this sale can be found here. Insiders have sold a total of 56,828 shares of company stock worth $3,350,922 over the last ninety days. 2.80% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in AMED. Sivik Global Healthcare LLC increased its stake in shares of Amedisys by 60.9% in the first quarter. Sivik Global Healthcare LLC now owns 34,607 shares of the health services provider’s stock valued at $1,768,000 after buying an additional 13,097 shares in the last quarter. OppenheimerFunds Inc. increased its stake in shares of Amedisys by 3.5% in the first quarter. OppenheimerFunds Inc. now owns 446,147 shares of the health services provider’s stock valued at $22,794,000 after buying an additional 15,289 shares in the last quarter. Thrivent Financial For Lutherans increased its stake in shares of Amedisys by 3.8% in the first quarter. Thrivent Financial For Lutherans now owns 15,703 shares of the health services provider’s stock valued at $802,000 after buying an additional 570 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Amedisys during the fourth quarter valued at $870,000. Finally, Great West Life Assurance Co. Can increased its stake in shares of Amedisys by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock valued at $2,045,000 after buying an additional 2,960 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.